Jun 20 |
Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor
|
Jun 14 |
3 Blue-Chip Stocks to Triple Your Wealth by 2026: June Edition
|
Jun 11 |
‘Load Up,’ Says Goldman Sachs About These 2 Strong Buy Stocks
|
Jun 5 |
Goldman starts Jazz at buy, cites diversified portfolio
|
Jun 3 |
7 Overlooked Stocks Offering Long-Term Stability From the Shadows
|
Jun 1 |
Jazz presents additional phase 2 data on zanidatamab for biliary tract cancer
|
Jun 1 |
Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024
|
May 31 |
Why Is Jazz (JAZZ) Down 3.5% Since Last Earnings Report?
|
May 30 |
Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024
|
May 29 |
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
|